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Abstract: We report on a patient in whom the use of antiglaucoma drugs has been beneﬁ  cial 
for the attainment of monovision after laser in situ keratomileusis (LASIK). A 57-year-old 
woman undergoing LASIK complained of blurred vision in the right eye. After a successful 
trial of monovision with contact lenses, antiglaucoma drugs (2.5% nipradilol) were administered 
topically to the right eye twice a day to establish monovision. In the right eye, the manifest 
refraction was changed from −4.0, −1.0 × 80, with an uncorrected visual acuity (UCVA) of 
0.3 for near vision before treatment, to −2.5, −1.0 × 80, with an UCVA of 0.9 for near vision 
after treatment, while, in the left eye, it was 0, −1.0 × 100, with an UCVA of 0.9 for far vision. 
Binocular UCVA was improved from 0.3 for near and 0.9 for distance vision before treatment, 
to 0.9 for near and 1.0 for distance vision after treatment. No complications were observed 
and the manifest refraction remained stable during the 6-month follow-up period. The use of 
antiglaucoma drugs may be helpful for the achievement of monovision by reduction of myopic 
regression after LASIK.
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Introduction
Excimer laser surgery has for years been a routine procedure for the correction of 
myopia, hyperopia, and astigmatism. However, myopic regression of the initial surgical 
effect can affect the predictability, efﬁ  ciency, and long-term stability of keratorefrac-
tive surgery, leading to deterioration in visual performance. Actually, it is well known 
that some regression may occur not only after photorefractive keratectomy (PRK) 
but also after laser in situ keratomileusis (LASIK), especially when the amount of 
myopic correction is large,1–5 but the mechanism for myopic regression still remains 
to be elucidated. We have already shown that antiglaucoma drugs are effective for the 
reduction of refractive regression after LASIK.6
Monovision has been reported to be an effective method for the management of 
presbyopia where the one eye is corrected for distance vision and the other for near. 
It has also been used for presbyopic patients after LASIK.7,8 Nonetheless, to our 
knowledge, there have been no previous case reports on the management of monovi-
sion after LASIK with the use of antiglaucoma drugs in eyes with presbyopia. We 
present herein a case in which the use of antiglaucoma eye drops was helpful for the 
establishment of monovision by reducing regression after LASIK.
Case report
A 57-year-old woman, who had undergone bilateral LASIK to correct myopia 
of −11.75 diopters (D) in both eyes eight years earlier, was referred to our hospi-
tal with a complaint of blurred near vision in the right eye. The manifest refrac-
tion was −4.0, −1.0 × 80, with an uncorrected visual acuity (UCVA) of 0.3 for 
near and 0.07 for distance vision, and a best spectacle-corrected visual acuity 
(BSCVA) of 1.2 in the right eye, and was 0, −1.0 × 100, with an UCVA of 0.9 and a BSCVA Clinical Ophthalmology 2009:3 212
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of 1.2 in the left eye. Binocular UCVA was 0.3 for near and 
0.9 for distance vision. The keratometry was 40.8/41.3 D × 170; 
the central corneal thickness (CCT), 433 μm; and the intra-
ocular pressure (IOP), 11 mmHg in the right eye (Table 1). 
Scanning-slit corneal topography (Orbscan; Bausch and 
Lomb, Rochester, NY, USA) showed a marked central thin-
ning of the cornea (Figure 1). Other ophthalmic examination 
ﬁ  ndings were unremarkable. The left eye was dominant, and 
the right eye, nondominant according to the hole-in-card 
test. We conﬁ  rmed a successful trial of monovision with 
contact lenses. After informed consent was obtained from the 
patient, topical antiglaucoma drugs (2.5% nipradilol; Kowa, 
Tokyo, Japan) were continuously administered to the right 
eye twice a day to establish monovision. At 1 month after 
application, the mean refraction was −2.5, −1.00 × 80, with 
an UCVA of 0.9 for near and 0.15 for distance vision, and a 
BSCVA of 1.2. Binocular UCVA was 0.9 for near and 1.0 for 
distance vision. The keratometry was 39.8/40.3 D × 175 in 
the right eye. The CCT was 434 μm. The IOP was 9 mmHg 
(Table 1). No vision-threatening complications occurred, and 
the manifest refraction remained unchanged, throughout the 
six-month observation period.
Discussion
In this case, the near UCVA was 0.3 and the manifest 
refraction was −4.0, −1.0 × 80 in the right eye, which was 
insufﬁ  cient for achieving monovision with good near vision, 
and the patient complained of anisometropic asthenopia. 
Moreover, enhancement surgery should be avoidable because 
of its side effect of biomechanical weakening of the cornea 
as evidenced by a marked central thinning (CCT, 433 μm, 
thinnest CT, 408 μm). We have already demonstrated 
that antiglaucoma drugs are effective for the reduction 
of myopic regression, especially that of spherical errors, 
which presumably results from the backward movement of 
the cornea and the ﬂ  attening of its curvature after LASIK 
without affecting CCT.6 On the assumption that monovision 
is likely to be established if the small amount of regression 
in the right eye can be reduced, we performed an additional 
antiglaucoma treatment to that eye only in this case. Although 
excessive monovision may be unacceptable to the patient, it 
was clinically acceptable to this patient aged 57 years with 
an anisometropia of 2.5 D. At present, we have no clear 
explanation of why the refraction was improved by as much 
as 1.5 D in this case. We have already demonstrated that cor-
neal biomechanical parameters are decreased not only in eyes 
with thinner CCT,9 but also in the eyes of older patients.9,10 
We speculate that the corneal biomechanical changes due 
to a thin cornea and increasing patient age may contribute 
to the unexpected refractive outcomes in this case, because 
these changes tend to induce greater ﬂ  attening of the cornea, 
leading to greater refractive improvement.
Nipradilol, a nonselective alpha-1 beta adrenergic 
antagonist with nitroglycerine-like activity, is widely used 
in Japan as a safe and useful long-term antihypertensive drug 
that lowers IOP by decreasing the aqueous ﬂ  ow rate and by 
increasing uveoscleral outﬂ  ow,11,12 although it is contrain-
dicated for the patients with cardiovascular disease or with 
asthma. Therefore, we selected it as the therapeutic option 
for the regressive eye.
There are concerns about the possible long-lasting effects 
of the treatment. If the refractive effects depend simply on 
the degree of IOP reduction, patients could be compelled to 
use the antiglaucoma drugs continuously. We are planning 
further studies to conﬁ  rm whether or not this refractive effect 
is maintained after long-term cessation of the medication.
Table 1 Patient demographics before and after nipradilol treatment
Pre-treatment Post-treatment (1 mo)
Monocular (right eye, nondominant)
Mean refraction −4.0, −1.0 × 80 −2.5, −1.0 × 80
Near UCVA 0.3 0.9
Far UCVA 0.07 0.15
Keratometry (D) 40.8/41.3 D × 170 39.8/40.3 D × 175
CCT (μm) 433 434
IOP (mmHg) 11 9
Binocular
Near UCVA 0.3 0.9
Far UCVA 0.9 1.0
Abbreviations: mo, month; UCVA, uncorrected visual acuity; CCT, central corneal thickness; IOP, intraocular pressure.Clinical Ophthalmology 2009:3 213
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Our case report suggests that the use of antiglaucoma 
drugs may contribute to the reduction of refractive 
regression, resulting in the achievement of monovision 
after LASIK in eyes with presbyopia. Although we accept 
that it does not frequently occur that antiglaucoma drugs 
are effective for the attainment of monovision after LASIK 
in the manner shown in this case, we believe that this 
treatment is clinically applicable especially to biomechani-
cally weakened eyes such as those with thinned corneas 
after LASIK, because it appeared to be less invasive 
and to cause fewer side effects (eg, keratectasia) than 
enhancement surgery.
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Figure 1 The scanning-slit corneal topography displays marked central thinning of the cornea.